Clinical trials: Respiratory Syncytial Viruses
- Condition Respiratory Syncytial Viruses
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Respiratory Syncytial Viruses
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
Globally, respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease (LRTD) in infants and children.
- Trial name
- CASSATT (NCT06813872)
- Testing
- ABRYSVO Vaccination
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Respiratory Syncytial Viruses, Respiratory Tract Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age
The purpose of this study is to assess the safety and tolerability of an intramuscular regimen of two doses (1*10^11 viral particles [vp]) of an investigational respiratory syncytial virus (RSV) vaccine candidate (adenovirus…
- Trial name
- NCT03303625
- Testing
- Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp)
- Where
- 7 sites in United States, Finland and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Respiratory Syncytial Viruses
A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
The purpose of this two-part designed study is to assess in the setting of a planned early interception of pediatric RSV disease, early viral and disease kinetics (observational stage) and the antiviral effects of an Respiratory…
- Trial name
- NCT04068792
- Testing
- RSV Mobile Application, JNJ-53718678 2.5 mg/kg, JNJ-53718678 3 mg/kg
- Where
- 10 sites in Argentina, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Syncytial Viruses
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity…
- Trial name
- NCT03333317
- Testing
- Lumicitabine
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Syncytial Viruses, Respiratory Tract Infection
Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children
The primary objective of this study is to determine the incidence of severe RSV LRTI requiring hospitalization among infants born < 35 weeks gestational age for one year of follow-up.
- Trial name
- NCT00585481
- Testing
- Samples collection for viral diagnosis, Lung Function Analysis
- Where
- 2 sites in Brazil
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Abbott